A clinical trial in China testing ICP-538, a treatment candidate for MS and other autoimmune diseases, has dosed its first ...

A.J.S. Rayl's article on the possibility of an oral treatment for multiple sclerosis 1 (MS) once again points out the need for new thinking about the causes and treatments for MS. For over 50 years, ...

Two injectable therapies accounted for nearly 100 percent of medications for patients in 2001, but by 2020 that decreased to about 25 percent. The majority of individuals with multiple sclerosis (MS) ...

A second clinical trial testing fenebrutinib for MS has met its main goal, once again beating approved Aubagio in reducing ...

Fingolimod (FTY720), an immunomodulator that acts on sphingosine-1-phosphate receptors, is the first oral disease-modifying agent to be approved by the US FDA for the treatment of relapsing forms of ...

WASHINGTON (Reuters) - U.S. regulators on Wednesday approved a new multiple sclerosis drug made by Biogen Idec Inc that is widely expected to become the No. 1 oral treatment for the disease, with ...

NEW YORK (Reuters Health) - In people with multiple sclerosis, or MS, treatment with a new immune-modulating drug called laquinimod can significantly reduce disease activity seen on brain MRI scans, a ...

When I was diagnosed with multiple sclerosis, or MS, back in 1988, there were no treatments on the market. The only prescription I received then was a recommendation to go home and rest. It wasn’t ...

Drs Fazal and Zeidan illustrate the roles and challenges of implementing oral therapies in MDS treatment management. Ryan Haumschild, PharmD, MS, MBA: Dr Fazal, when we’re looking at patients, there ...

† Referred to as immunomodulatory treatments. ‡ Considered to be an immunosuppressant therapy. CIS: Clinically isolated syndrome; IM: Intramuscular; IV ...